Related Experiment Videos
Penetration of cefuzoname into the cerebrospinal fluid of rabbits
Abstract:
Concentrations of cefuzoname in cerebrospinal fluid (CSF) were determined in a total of 16 rabbits, 5 with healthy meninges, 5 with Staphylococcus aureus meningitis, and 6 with Escherichia coli meningitis. Mean percentages of the maximum concentration of the drug in CSF versus that in serum were 0.57, 3.37, and 4.40% for healthy rabbits, those with staphylococcal meningitis, and those with E. coli meningitis, respectively. The percentages of the area under the concentration-time curve of cefuzoname in CSF versus that in serum were, in the order of healthy group, staphylococcal meningitis group, and E. coli meningitis group, 0.61, 4.99, and 8.04% at 15 to 60 min, 1.44, 7.09, and 12.7% at 15 to 120 min, and 1.87, 8.07, and 15.8% at 15 to 180 min after administration, showing significant differences between the healthy and meningitis groups. All of the values in the E. coli meningitis group were greater than those of the staphylococcal meningitis group, but the differences were not significant. The ratios of the half-life of cefuzoname in CSF to that in serum were 2.10, 1.98, and 3.37 for the healthy, staphylococcal meningitis, and E. coli meningitis groups, respectively, with no significant difference between the three groups. Cefuzoname seems to be among the middle ranks of beta-lactam agents as far as penetration rate is concerned; however, when its potent antibacterial activity and broad spectrum are taken into account, the concentrations in CSF in patients with meningitis seem worth examining.
Insights
Cefuzoname penetration into cerebrospinal fluid (CSF) is higher in rabbits with bacterial meningitis than in healthy ones. These findings suggest cefuzoname CSF concentrations warrant further investigation for meningitis treatment.
Area of Science:
- Pharmacology
- Infectious Diseases
- Neuroscience
Background:
- Bacterial meningitis requires effective antibiotic penetration into the cerebrospinal fluid (CSF).
- Understanding cefuzoname's CSF penetration is crucial for evaluating its therapeutic potential in meningitis.
Purpose of the Study:
- To quantify cefuzoname concentrations in the CSF of rabbits with experimentally induced bacterial meningitis.
- To compare cefuzoname's CSF penetration in healthy rabbits versus those with Staphylococcus aureus or Escherichia coli meningitis.
Main Methods:
- Cefuzoname concentrations were measured in serum and CSF of rabbits.
- Rabbits were divided into healthy, S. aureus meningitis, and E. coli meningitis groups.
- Key pharmacokinetic parameters including Cmax, AUC, and half-life ratios were calculated.
Main Results:
- CSF cefuzoname concentrations were significantly higher in meningitis models compared to healthy controls.
- Mean CSF to serum penetration percentages (AUC) were 0.61% (healthy), 4.99% (S. aureus), and 8.04% (E. coli) at 15-60 min.
- CSF to serum half-life ratios showed no significant differences across groups.
Conclusions:
- Cefuzoname exhibits enhanced penetration into the CSF during experimental bacterial meningitis.
- Despite moderate penetration rates, cefuzoname's efficacy and spectrum may justify its clinical consideration for meningitis.
- Further studies are needed to confirm cefuzoname's clinical utility in treating meningitis.